Description

Illumina: What’s Behind The NovaSeq X Transition & Its Bigger Consumables Opportunity?

Illumina reported a first quarter 2026 revenue of $1.09 billion, exceeding expectations primarily due to strong performance in instrument sales and clinical consumables. The company’s revenue grew 4.8% year-over-year, with 1.2% organic growth after adjusting for currency and acquisitions. Growth was driven largely by a 3.5% organic increase in Rest of World sequencing revenue, including approximately 7% growth in sequencing consumables and a 20% expansion in clinical consumables ex-China. Sequencing instruments revenue rose 9% year-over-year, propelled by more than 80 placements of the NovaSeq X platform, marking a demand surge across clinical and research markets. However, this quarter reflected supply constraints in NovaSeq X units, limiting the number of placements. Illumina’s clinical sequencing consumables made up over 65% of consumables revenue, supported by new assay launches and progress in reimbursement, while research and applied markets remained cautious, leading to a 12% decline in sequencing consumables ex-China.